Trial Profile
Clinical Outcome of de Novo Everolimus-based Immunosuppressive Therapy for Renal Transplantation Using Rituximab Induction
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Rituximab (Primary) ; Antithymocyte globulin; Corticosteroids; Mycophenolate mofetil; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 16 Mar 2011 New trial record